Atossa Therapeutics (ATOS) Liabilities and Shareholders Equity (2011 - 2026)

Atossa Therapeutics (ATOS) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $37.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 46.37% year-over-year to $37.9 million; the TTM figure through Mar 2026 stood at $208.1 million (down 33.42% YoY), while the FY2025 annual figure was $47.6 million, down 37.72% from the prior year.
• Liabilities and Shareholders Equity declined to $37.9 million in Q1 2026 per ATOS's latest filing, from $47.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $137.5 million in Q1 2022 and bottomed at $37.9 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $91.5 million across 5 years, with a median of $91.1 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity decreased 2.55% — and 2026, when it sank 46.37%.
• Atossa Therapeutics' Liabilities and Shareholders Equity stood at $123.5 million in 2022, then fell by 22.08% to $96.3 million in 2023, then fell by 20.58% to $76.4 million in 2024, then sank by 37.72% to $47.6 million in 2025, then retreated by 20.3% to $37.9 million in 2026.
• Business Quant data shows ATOS's Liabilities and Shareholders Equity at $37.9 million in Q1 2026, $47.6 million in Q4 2025, and $58.0 million in Q3 2025.